SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (9914)10/21/1997 3:27:00 PM
From: Henry Niman  Respond to of 32384
 
Andy, Lehman Brothers says LGND's license will be a LLY drug approved next year.



To: Andrew H who wrote (9914)10/21/1997 3:33:00 PM
From: Henry Niman  Read Replies (2) | Respond to of 32384
 
Andy, I just looked at:
ascp.com
and the only LLY drug to fit the bill was Evista :-).
I just went to LLY's drugs in clinical trials at:
elililly.com
and the only cancer drug was a multitarget antifolate. Gemciyabine for bladder and breast cancer would fit, but it looks like its already approved for non-small cell lung and pancreatic cancer.
For osteoporosis they have Raloxifene (Evista), Parathyroid Hormone, and Recombinant glucagon.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News